Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Deepak Bhatt acquired deferred share units convertible to common stock in Bristol-Myers Squibb on September 30, 2024.

Summary

• On September 30, 2024, Deepak Bhatt, a director of Bristol-Myers Squibb, acquired 169.115 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Bhatt ceases to be a director or at a previously specified future date.
• The price per unit was $51.74.
• Following the transaction, Bhatt beneficially owns 10,696.087 shares, including deferred compensation and reinvested dividends.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction. The director's acquisition of deferred share units indicates continued alignment with the company's performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures of insider transactions and provide transparency regarding the holdings of company directors and officers. This filing indicates a director's continued investment in the company.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence as it reflects a director's continued investment in the company.

Key Dates